May 17, 2022
Life Sciences
  • Twenty-four states filed a legal brief supporting the federal government’s battle against six drugmakers over 340B restrictions. The states said that the drugmakers – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics – unlawfully cut off sales of 340B drugs to contract pharmacies. According to the states, contract pharmacies are vital to helping dispense drugs for outpatient treatment and recovery and the “new policies are an improper way to remedy any disputes regarding duplicate reimbursements or drug diversion.” (Article here)